Publication: Rare Disease Advisor
Abstract
The article, “Move Away From Animal-Only Testing May Improve, Speed Rare Disease Research,” explores a growing trend to reduce reliance on animal testing in rare disease research. This shift, driven by health regulators in the US, is aimed at accelerating the development of treatments for rare diseases while improving accuracy and reducing ethical concerns. Emerging alternatives to traditional preclinical models are highlighted as game-changing innovations, offering more relevant and efficient testing pathways.
Published: Aug 15, 2025
Innovative solutions for rare diseases
Rare diseases often face unique obstacles such as small patient populations, sensitive clinical profiles, and complex regulatory pathways. Certara integrates model-informed drug development (MIDD) strategies to address these complexities. By leveraging quantitative models, regulatory expertise, and real-world data, we empower our partners to fast-track innovative therapies while meeting stringent regulatory standards.
